Prostate cancer: are new prognostic markers on the horizon?

Lijovic, Marijana; Fabiani, Maurice E.; Bader, Julia; Frauman, Albert G

doi:10.1038/sj.pcan.4500408

Cited by 7 publications

(10 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,17 Despite recent intensive research investigations, much remains to be learned about specific molecular defects associated with CaP onset and progression. 5,[18][19][20][21][22] Our laboratory is focusing on the discovery of new biomarkers for CaP diagnosis, prognosis and treatment. These efforts resulted the identification of numerous prostate specific/abundance and/or CaP-associated genes.…”

Section: Discussionmentioning

confidence: 99%

Quantitative expression profile of PSGR in prostate cancer

Sun

Petrovics

et al. 2005

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

PSGR is a novel member of the G-protein-coupled olfactory receptor family. Our initial report showed predominant expression of the PSGR in human prostate gland and significant alterations of PSGR expression in primary prostate cancer (CaP) specimens. The aim of this study was to provide in-depth evaluations of the expression profile of PSGR in prostatic epithelial cells of CaP patients and to evaluate the association of PSGR expression characteristics with clinico-pathologic features. In total, 220 RNA specimens, from laser capture microdissected paired benign and malignant prostatic epithelial cells of 110 CaP patients, were analyzed for PSGR expression by quantitative real-time PCR. The differential expression of PSGR between the prostatic epithelial cells of malignant and benign glands was statistically significant (Po0.0001). Comparison of PSGR expression between paired benign and tumor cells revealed prostate tumor cell-specific overexpression in 67.2% of tumor specimens (74 of 110), decreased expression in 20.9% of tumor specimens (23 of 110) and no difference of PSGR expression between tumor and normal cells in 11.8% of specimens (13 of 110). In representative cases, PSGR expression patterns were independently confirmed by in situ RNA hybridization. The PSGR overexpression associated with higher percentage of pathologic stage, pT3, and a higher level of preoperative serum PSA. CaP cells of African-American CaP patients exhibited about two-fold increase of PSGR expression in comparison to the Caucasian American CaP patients. Strikingly high-percentage CaP cells overexpress PSGR warrants further studies of PSGR expression alterations to define subsets of CaPs.

show abstract

Section: Discussionmentioning

confidence: 99%

Quantitative expression profile of PSGR in prostate cancer

Sun

Petrovics

et al. 2005

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Prostate cancer is a leading cause of morbidity and mortality in males, accounting for ∼30% of all new cases of cancer and ∼14% of cancer deaths 1. Despite the high prevalence (∼27%) of prostate cancer in autopsy series in 30‐40‐year‐old patients,2 the lifetime probability of being diagnosed with prostate cancer is 8%, whereas the probability of dying of prostate cancer is 3% 3.…”

Section: Introductionmentioning

confidence: 99%

Biological Selection Criteria for Radical Prostatectomy

Muzzonigro¹,

Galosi²

2002

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Tumors clinically confined to the prostate gland (T1‐2) are heterogeneous with respect to pathological staging and outcome after definitive radical surgery (radical prostatectomy). The preoperative prognostic factors that could predict pathological stage and outcome of individual patients with clinically localized prostate cancer are reviewed. New preoperative factors have been identified by histological analysis of needle biopsy prostate specimens in addition to Gleason grading score, serum markers (PSA), and clinical staging. These factors are related to tumor volume, zonal origin of the tumor, and spread into the gland and surrounding tissues. Other biological factors are identified by molecular and immunohistochemical analysis (neuroendocrine differentiation, DNA content, microvessel density, and perineural invasion). Biomolecular factors can also be assessed preoperatively on serum samples (free/total PSA ratio, PSA RT‐PCR). Although only a few of these factors have a role in predicting treatment failure and/or disease recurrence, the neural network analysis seems to be the most important tool for identifying patients with more aggressive disease. A combination of these new factors, also using neural networks, could be relevant in the preoperative management of patients with prostate cancer to identify those with confined disease and to select those suitable for a “nerve sparing radical prostatectomy” to preserve sexual function and to achieve definitive cancer control.

show abstract

“…One of the main issues for the clinicians and pathologists involved in the field of prostate cancer (PCa) [1,2] is the identification of those prognostic factors that could predict accurately the outcome of individual patients with PCa. The contemporary status of the prognostic factors was addressed in two recent international consensus conferences: 1999 College of American Pathologists (CAP)…”

Section: Prognostic Factorsmentioning

confidence: 99%